Slingshot members are tracking this event:
FDA Designates Immunomedics' (IMMU) IMMU-132 a Breakthrough Therapy for Treatment of Triple Negative Breast Cancer (TNBC)
Slingshot Insights Explained
Feb 05, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Immu-132, Braekthrough Therapy Designation, Triple Negative Breast Cancer, Resistant To Therapy